Literature DB >> 30023385

Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?

Yuki Kataoka1,2, Katsuya Hirano2.   

Abstract

Year:  2018        PMID： 30023385      PMCID： PMC6035987          DOI： 10.21037/atm.2018.04.17

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  19 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Authors:  M Tazdait; L Mezquita; J Lahmar; R Ferrara; F Bidault; S Ammari; C Balleyguier; D Planchard; A Gazzah; J C Soria; A Marabelle; B Besse; C Caramella
Journal:  Eur J Cancer       Date:  2017-11-26       Impact factor: 9.162

3.  Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.

Authors:  Yuki Kataoka; Katsuya Hirano; Tomoko Narabayashi; Satoshi Hara; Daichi Fujimoto; Tae Tanaka; Noriyuki Ebi; Keisuke Tomii; Hiroshige Yoshioka
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-11       Impact factor: 3.333

4.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Authors:  Stefan Diem; Sabine Schmid; Mirjam Krapf; Lukas Flatz; Diana Born; Wolfram Jochum; Arnoud J Templeton; Martin Früh
Journal:  Lung Cancer       Date:  2017-07-24       Impact factor: 5.705

5.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Authors:  Caroline Robert; Antoni Ribas; Omid Hamid; Adil Daud; Jedd D Wolchok; Anthony M Joshua; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Richard W Joseph; Roxana Dronca; Amita Patnaik; Hassane Zarour; Richard Kefford; Peter Hersey; Jin Zhang; James Anderson; Scott J Diede; Scot Ebbinghaus; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2017-12-28       Impact factor: 44.544

6.  Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Maria Gargano; Margaret Suda; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2013-06-06       Impact factor: 12.531

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

9.  Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.

Authors:  Leila Khoja; Minnie Kibiro; Ur Metser; Craig Gedye; David Hogg; Marcus O Butler; Eshetu G Atenafu; Anthony M Joshua
Journal:  Br J Cancer       Date:  2016-10-04       Impact factor: 7.640

10.  Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

Authors:  S Diem; B Kasenda; L Spain; J Martin-Liberal; R Marconcini; M Gore; J Larkin
Journal:  Br J Cancer       Date:  2016-01-21       Impact factor: 7.640
View more
  7 in total

1.  Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.

Authors:  Sungmin Woo; Chong Hyun Suh; Andreas G Wibmer; Anton S Becker; Min Yuen Teo; Mithat Gönen; Hedvig Hricak; Howard I Scher; Michael J Morris; Hebert Alberto Vargas
Journal:  Clin Genitourin Cancer       Date:  2021-11-15       Impact factor: 2.872

2.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

Review 3.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.

Authors:  Stefano Frega; Alessandro Dal Maso; Giulia Pasello; Lea Cuppari; Laura Bonanno; PierFranco Conte; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 4.  Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead.

Authors:  Basak Aru; Mojdeh Soltani; Cemil Pehlivanoglu; Ege Gürlü; Mazdak Ganjalikhani-Hakemi; Gülderen Yanikkaya Demirel
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

5.  Classical mathematical models for prediction of response to chemotherapy and immunotherapy.

Authors:  Narmin Ghaffari Laleh; Chiara Maria Lavinia Loeffler; Julia Grajek; Kateřina Staňková; Alexander T Pearson; Hannah Sophie Muti; Christian Trautwein; Heiko Enderling; Jan Poleszczuk; Jakob Nikolas Kather
Journal:  PLoS Comput Biol       Date:  2022-02-04       Impact factor: 4.475

Review 6.  In vivo Imaging Technologies to Monitor the Immune System.

Authors:  Claire E McCarthy; Jordan M White; Nerissa T Viola; Heather M Gibson
Journal:  Front Immunol       Date:  2020-06-02       Impact factor: 8.786

7.  Imaging of tumour response to immunotherapy.

Authors:  Clarisse Dromain; Catherine Beigelman; Chiara Pozzessere; Rafael Duran; Antonia Digklia
Journal:  Eur Radiol Exp       Date:  2020-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.